The notices it replaced
2 notices since 2019, oldest first, each with its awards since FY2014.
- Posted 2019RFA-HL-20-02211 awards
- Posted 2022RFA-HL-23-0109 awards
- Posted 2024RFA-HL-26-016This notice, open · 4 awards
Who won it before
Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.
- Past awards
- 24
- 24 new
- Median first-year cost
- $477,623
- $11,312,723 in all
- Institutions
- 22
- 23 contact PIs
Awards by fiscal year
0
0
0
0
0
0
3
3
5
3
4
2
4
14151617181920212223242526
Fiscal years 2014 to 2026.
Most frequent institutions
- BRIGHAM AND WOMEN'S HOSPITAL2
- STANFORD UNIVERSITY2
- 3D BIOANALYTIX, INC.1
- ALBERT EINSTEIN COLLEGE OF MEDICINE1
- HALCYON BIOMEDICAL, INC.1
and 17 other institutions
Most frequent study sections
- Special Emphasis Panel (ZHL1 CSR-O (O1))6
- Special Emphasis Panel (ZHL1 CSR-O (F1))3
- Special Emphasis Panel (ZHL1 CSR-O (M2))3
- Special Emphasis Panel (ZRG1 MCST-Y (56))3
- Special Emphasis Panel (ZHL1 CSR-O (F2))2
and 5 other study sections
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| FY2026 | A streamlined base editor reengineering platform to enhance gene editing specificity and selectivity1R33HL185498-01 | Jiang, Tingting | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | First-year cost $570,666 | Study section ZRG1 |
| FY2026 | High-throughput, multi-parametric assessment of cardiomyocyte viscoelasticity and contractility to enable HFpEF drug discovery1R33HL187274-01 | Mercola, Mark | STANFORD UNIVERSITY, CA | First-year cost $509,334 | Study section ZRG1 |
| FY2026 | A Transformative Structural Proteomics Platform for Early Detection of Misfolding-Driven Cardiovascular Diseases1R33HL185603-01 | Pankow, SandraYates Iii, John R | 3D BIOANALYTIX, INC., CA | First-year cost $421,400 | Study section ZRG1 |
| FY2026 | Development and validation of a cell separation platform technology1R33HL183009-01 | Gifford, Sean | HALCYON BIOMEDICAL, INC., TX | First-year cost $351,949 | Study section ZRG1 |
| FY2025 | Drug Coated Balloon Peptide Delivery to Block Post-angioplasty Restenosis in PAD1R33HL181752-01 · under RFA-HL-23-010 | Duvall, Craig Lewis | VANDERBILT UNIVERSITY, TN | First-year cost $489,644 | Study section ZHL1 |
| FY2025 | Development of platform technology to measure kinetics and equilibrium concentration of sickle hemoglobin polymerization in single RBCs for drug potency assessment and patient risk stratification1R33HL173898-01A1 · under RFA-HL-23-010 | Higgins, John Matthew | MASSACHUSETTS GENERAL HOSPITAL, MA | First-year cost $483,852 | Study section ZHL1 |
| FY2024 | Flexible bioelectronics platform converging capillary-like delivery network and sensing feedback network for improving cardiac tissue engineering1R33HL175683-01 · under RFA-HL-23-010 | Yao, Jun | UNIVERSITY OF MASSACHUSETTS AMHERST, MA | First-year cost $488,026 | Study section ZHL1 |
| FY2024 | A Novel Ticagrelor Coated Stent to Eliminate the Need for Dual Anti Platelet Therapy Post PCI1R33HL171775-01 · under RFA-HL-23-010 | Pacella, John J | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | First-year cost $481,245 | Study section ZHL1 |
| FY2024 | Advancement of an Impending Hospitalization Detection Platform1R33HL168785-01A1 · under RFA-HL-23-010 | King, Kevin R | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | First-year cost $474,000 | Study section ZHL1 |
| FY2024 | Towards systematic analysis of cardiac voltage-gated sodium channel beta subunit function1R33HL168768-01A1 · under RFA-HL-23-010 | Ahern, Christopher APiper, Robert C | UNIVERSITY OF IOWA, IA | First-year cost $466,355 | Study section ZHL1 |
| FY2023 | A New Lipid Nanoparticle Technology Enabling Long-acting mRNA Therapy1R33HL168751-01 · under RFA-HL-23-010 | Shi, Jinjun | BRIGHAM AND WOMEN'S HOSPITAL, MA | First-year cost $542,677 | Study section ZHL1 |
| FY2023 | Optimization of electromechanical monitoring of engineered heart tissues1R33HL168758-01 · under RFA-HL-23-010 | Efimov, Igor RMcNally, Elizabeth MRogers, John | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | First-year cost $466,698 | Study section ZHL1 |
| FY2023 | High throughput platform for simultaneous multiparametric assessment of cardiac physiology for heart failure drug development1R33HL167258-01A1 · under RFA-HL-23-010 | Mercola, Mark | STANFORD UNIVERSITY, CA | First-year cost $463,200 | Study section ZHL1 |
| FY2022 | The genetically engineered pig heart as a bridge to allotransplantation in infants1R33HL163718-01 · under RFA-HL-20-022 | Cleveland, David C | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | First-year cost $488,333 | Study section ZHL1 |
| FY2022 | MPI/MRI bimodal imaging for non-invasive tracking of extracellular vesicles targeted to infarcted myocardium1R33HL161756-01 · under RFA-HL-20-022 | Liu, Guanshu | HUGO W. MOSER RES INST KENNEDY KRIEGER, MD | First-year cost $487,071 | Study section ZHL1 |
| FY2022 | Hyperpolarized Carbon-13 Metabolic MRI of the Human Heart1R33HL161816-01 · under RFA-HL-20-022 | Abraham, Maria RoselleLarson, Peder Eric Zufall | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | First-year cost $482,538 | Study section ZHL1 |
| FY2022 | Beat-to-Beat Blood Pressure Monitoring During Sleep1R33HL163749-01 · under RFA-HL-20-022 | Kim, Joshua | VENA VITALS, INC., CA | First-year cost $415,577 | Study section ZHL1 |
| FY2022 | An Enabling Technology for Human Cardiomyocyte Manufacturing1R33HL163711-01 · under RFA-HL-20-022 | Lei, Yuguo | PENNSYLVANIA STATE UNIVERSITY, THE, PA | First-year cost $413,610 | Study section ZHL1 |
| FY2021 | Exhaled small RNA biomarkers to detect and monitor airway disease1R33HL156279-01 · under RFA-HL-20-022 | Loudig, OlivierSpivack, Simon D | ALBERT EINSTEIN COLLEGE OF MEDICINE, NY | First-year cost $532,716 | Study section ZHL1 |
| FY2021 | Dynamic tissue-specific modulation of redox stress using chemogenetics1R33HL157918-01 · under RFA-HL-20-022 | Michel, Thomas | BRIGHAM AND WOMEN'S HOSPITAL, MA | First-year cost $513,644 | Study section ZHL1 |
| FY2021 | Developing EPR tools for preclinical interrogation of redox regulation mechanisms contributing to acute lung injury1R33HL157907-01 · under RFA-HL-20-022 | Eaton, Sandra S.Nozik, Eva S. | UNIVERSITY OF COLORADO DENVER, CO | First-year cost $409,657 | Study section ZHL1 |
| FY2020 | An inflammation-induced fibrosis-on-chip system for the testing of anti-fibrosis drugs1R33HL154117-01 · under RFA-HL-20-022 | Zhao, Ruogang | STATE UNIVERSITY OF NEW YORK AT BUFFALO, NY | First-year cost $460,967 | Study section ZHL1 |
| FY2020 | Development of a next-generation glycomics platform to enable glycan structure analyses for precision medicine1R33HL154123-01 · under RFA-HL-20-022 | Gundry, Rebekah L. | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | First-year cost $458,564 | Study section ZHL1 |
| FY2020 | Optimization of a Rabbit Retained Hemothorax Model for Evidence-Based Pharmacologic Interventions1R33HL154103-01 · under RFA-HL-20-022 | Florova, GalinaIdell, StevenKomissarov, Andrey | UNIVERSITY OF TEXAS HLTH CTR AT TYLER, TX | First-year cost $441,000 | Study section ZHL1 |
Newest fiscal year first, then first-year cost.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-14-0.3.3. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.